SPECIALTY QUANTITY LIMIT PROGRAM

TALTZ (ixekizumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Taltz (ixekizumab) 80 mg/mL prefilled syringe/autoinjector	1 syringe/ autoinjector per 28 days	8 syringes/ autoinjectors per 84 days	 Plaque psoriasis: 160 mg at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks Psoriatic arthritis: 160 mg at week 0, followed by 80 mg every 4 weeks Ankylosing spondylitis: 160 mg at week 0, followed by 80 mg every 4 weeks

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCE

1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2019.

Specialty Quantity Limit Taltz 1739-H P2019b.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.